Background: This retrospective study aimed to evaluate the efficacy of a 3.6-mg dose of pegfilgrastim for primary prophylaxis in Japanese breast cancer patients receiving dose-dense chemotherapy. Methods: Patients treated with adjuvant or neoadjuvant chemotherapy for early-stage breast cancer at the Tokyo-West Tokushukai Hospital were included in this analysis. Because 6 mg pegfilgrastim has not yet been approved for use in Japan, we compared the outcomes of a dose-dense doxorubicin and cyclophosphamide regimen plus 3.6 mg pegfilgrastim support with a conventional dose epirubicin and cyclophosphamide regimen. The incidence of febrile neutropenia, relative dose intensity, dose delay, dose reduction, regimen change and hospitalization because of neutropenia were assessed. Results: From November 2013 to March 2016, 97 patients with stage I-III invasive breast cancer were analyzed (dose-dense doxorubicin and cyclophosphamide plus 3.6-mg pegfilgrastim group, n = 41; epirubicin and cyclophosphamide group, n = 56; median ages, 49.0 and 48.5 years, respectively). Febrile neutropenia occurred during the first chemotherapy cycle in 7 of 56 patients (12.5%) in the epirubicin and cyclophosphamide group and 0 of 41 patients in the dose-dense doxorubicin and cyclophosphamide group (P = 0.02). The average relative dose intensities were 97.9% and 96.8%, respectively (P = 0.28), with corresponding dose delay rates of 4.9% (2/41) and 16.1% (9/56), respectively (P = 0.11) and dose reduction rates of 0% (0/41) and 7.1% (4/56), respectively (P = 0.16). Conclusions: Our results indicate the efficacy of a 3.6-mg pegfilgrastim dose for the primary prevention of febrile neutropenia in dose-dense doxorubicin-and cyclophosphamide-treated Japanese breast cancer patients.
Introduction
In an adjuvant setting, anthracycline-and taxane-based chemotherapies have yielded substantial benefits for patients with high-risk, early-stage breast cancers (1) (2) (3) (4) (5) . The Cancer and Leukemia Group B (CALGB) 9741 trial provided an important confirmation of the value of dose scheduling in curative breast cancer treatment; in particular, a dosedense schedule of doxorubicin (A) and cyclophosphamide (C) followed by paclitaxel is considered as an optimal paclitaxel-based adjuvant regimen for node-positive early breast cancer (6) .
The relative dose intensity (RDI) represents the relationship between the actual delivered chemotherapy dose and schedule and the intended dose and schedule described by the standard chemotherapy regimen. Previous studies have shown that RDI maintenance is associated with improved patient outcomes (7) (8) (9) . However, RDIs <85% have been found to compromise treatment outcomes (10, 11) . In a retrospective study of 6487 patients with lymph node-positive breast cancer, the chemotherapy dose level and intensity were found to correlate significantly with both overall (OS) and disease-free survival (DFS) such that optimal delivery of the planned chemotherapy schedule led to an improvement in OS and DFS (12) .
Neutropenia remains a frequent, dose-limiting cancer chemotherapy-related toxicity and leads to dose delays and reductions of planned chemotherapies (13) (14) (15) . Administration of granulocyte-colony stimulating factor (G-CSF) has been found to reduce various risks associated with neutropenia, such as life-threatening infections as well as chemotherapy dose reductions and delays that may compromise treatment outcomes. Pegfilgrastim, a sustained duration form of G-CSF, has been introduced for the treatment of chemotherapy-induced neutropenia, and the prophylactic administration of pegfilgrastim prior to the onset of neutropenia is expected to reduce the risk of infection and improve the likelihood of maintaining the planned chemotherapy dose intensity (16) (17) (18) (19) . According to the recommendations of the American Society of Clinical Oncology, National Comprehensive Cancer Network and European Organization for Research and Treatment of Cancer, the use of G-CSF as a primary prophylaxis against the risk of febrile neutropenia (FN) is warranted when the risk of FN is approximately ≥20%, either because of the chemotherapy regimen alone or a combination of the chemotherapy regimen and individual FN risk factors (20) (21) (22) .
A dose-finding study involving subjects from the United States and Europe recommended a 6-mg dose of pegfilgrastim once per chemotherapy cycle (17) . However, based on the results from internal clinical trials, the Japanese Ministry of Health, Labour and Welfare approved the use of 3.6 mg pegfilgrastim for the prevention of FN in September 2014. Although those trials involved triweekly regimens such as docetaxel, doxorubicin and cyclophosphamide (TAC) or docetaxel and cyclophosphamide (TC), dose-dense chemotherapy has not yet been investigated (23, 24) . Therefore, we evaluated the efficacy of 3.6-mg (i.e. reduced) dose of pegfilgrastim as a primary prophylaxis against FN.
The main objective of this study was to assess the incidence of FN during the initial chemotherapy cycles in breast cancer patients treated using dose-dense doxorubicin and cyclophosphamide (ddAC) plus 3.6 mg of pegfilgrastim as a primary prophylaxis against FN in a neoadjuvant or adjuvant setting in comparison with the incidence in patients treated using conventional dose epirubicin and cyclophosphamide (EC). Because, in our hospital EC therapy has been performed as anthracycline-based chemotherapy before the approval of 3.6 mg pegfilgrastim in September 2014. In addition, 6 mg pegfilgrastim has not yet been approved for use in Japan, and we compared the outcomes ddAC plus 3.6 mg pegfilgrastim with a conventional dose EC.
The secondary study objectives included an evaluation of the incidence of FN during all cycles of chemotherapy, RDI for each patient, and frequencies of dose delays, dose reductions, regimen changes and hospitalization because of neutropenia among the study patients.
Patients and methods

Patients
We conducted a retrospective review of the case notes of patients who were treated for breast cancer at the Tokyo-West Tokushukai Hospital between November 2013 and March 2016. Approval for this study was received from our central institutional review board, and general informed consent was obtained from all patients who received medical care at our hospital.
Study drug
Pegfilgrastim (G-Lasta ® ; Kyowa Hakko Kirin Co., LTD., Tokyo, Japan) was used at a fixed dose of 3.6 mg in identical prefilled syringes. All study drugs were administered via subcutaneous injection between 24 and 72 hours after completion of chemotherapy. /l and ≥100 × 10 9 /l, respectively. A delay of up to 14 days in the initiation of the subsequent cycle was allowed to achieve these hematologic parameters.
Treatment doses and schedules
Toxicity events were graded using the National Cancer Institute Common Toxicity Criteria, version 4.0. The incidence of a grade 3 or 4 critical adverse event (AE), including FN, in the previous chemotherapy cycle that necessitated a dose reduction led to a 20% reduction in the doxorubicin or epirubicin dosage in the subsequent cycle. Only one dose reduction was allowed per patient determined by the medical judgment of the attending physician.
Study procedures
In addition, we assessed the RDI for each patient and summarized data related to the incidence of FN, dose delay, dose reduction, regimen change and hospitalization because of neutropenia. Public holidays were excluded as a causative event from the dose delay analysis.
The patient inclusion criteria for this retrospective analysis were a diagnosis of early breast cancer received between November 2013 and February 2016 and the administration of an anthracycline-based chemotherapy in an adjuvant or neoadjuvant setting. These chemotherapies were administered according to different schedules based on the individual characteristics of the patient and the tumor. G-CSF support, including 3.6 mg fixed-dose pegfilgrastim (G-Lasta ® ), was administered as a primary prophylaxis for patients treated using the ddAC regimen either as a secondary prophylaxis or for the management of AEs at the attending physician's discretion.
The retrieved study data included patient age, body weight, body surface area (BSA), clinical stage, lymph node involvement, hormonal receptor status and human epidermal growth factor receptor 2 (HER2) status. Primary prophylactic anti-infection agents were not allowed except for patients at a high risk of infection as assessed by the attending physician. Patients who developed FN were allowed to receive prophylactic anti-infection agents during subsequent cycles on the basis of the medical judgment of the attending physician.
Definitions of RDI
RDI was defined as the delivered dose intensity and expressed as a percentage of the prescribed dose intensity. RDI of a multidrug regimen was calculated as the average of the RDIs for each individual drug in the regimen. The RDI was initially separately calculated for each component of the chemotherapy regimen (RDI of doxorubicin, epirubicin and cyclophosphamide). Finally, the average RDIs of the ddAC and EC regimens were derived according to the following equations:
Average RDI of ddAC = (RDI doxorubicin + RDI cyclophosphamide)/2
Average RDI of EC = (RDI epirubicin + RDI cyclophosphamide)/2.
Definitions of FN
Signs and symptoms of inflammation are often attenuated or absent in neutropenic patients. In this study, FN was defined according to the 2012 guideline on FN published by the Japanese Society of Medical Oncology (JSMO) as follows: an axillary temperature of >37.5°C and neutropenia with an ANC of <0.5 × 10 9 /L or an expected reduction in ANC to <0.5 × 10 9 /L during the next 48 hours.
Statistics
An unpaired t-test was used to compare the mean RDI values of the two treatment groups. The chi-squared test was used to evaluate the incidence of FN, dose delay, dose reduction, regimen change and hospitalization because of neutropenia. All statistical tests were conducted against a two-sided, alternative hypothesis using a significance level of 0.05 and a 95% confidence interval. The ystat 2008 software program (statistical program file developed using Microsoft Excel; Igakutoshoshuppan, Tokyo, Japan) was used for statistical analysis.
Results
Patient characteristics
From November 2013 to March 2016, 97 patients were analyzed; of these, 41 patients comprised the ddAC group and 56 comprised the EC group. The characteristics of the patients included in this study are shown in Table 1 .
The rates of breast cancer subtypes are presented in Table 1 . ER/ PR+,HER2− were 68.3% (28/41) and 23% (23/56) for the ddAC and EC groups, respectively. ER/PR+,HER2+ were 14.6% (6/41) and 21.4% (12/56), ER/PR−,HER2+ were 7.3% (3/41) and 19.6% (11/56), and ER/PR−,HER2− were 9.8% (4/41) and 17.9% (10/56) for the ddAC and EC groups, respectively. The distribution of the clinical stage and LN positivity is shown in Table 1 .
Toxicity profiles
The most frequently reported AEs are presented in Table 2 . During ddAC therapy, the most common AEs were nausea, anemia, oral mucositis, fatigue and vomiting. Treatment-related grade 3 AE was experienced by one (2.4%) patient, and no grade 4 or 5 AE was observed. During EC therapy, the most common AEs were nausea, anemia, leukopenia, oral mucositis, fatigue and vomiting. Treatment-related grade 3 AEs were experienced by five (8.9%) patients, and no grade 4 or 5 AE was observed. 
The incidence of FN during the first cycle of chemotherapy
We observed FN during the first cycle of chemotherapy in 7 of the 56 patients (12.5%) of the EC group. However, no patients in the ddAC group developed FN during the first cycle of chemotherapy (P = 0.02; Table 3 ).
The incidence of FN during all cycles of chemotherapy
One of 41 patients (2.4%) in the ddAC group developed FN during any cycle of chemotherapy compared with 8 of 56 patients (14.3%) in the EC group (P = 0.07; Table 3 ).
Relative dose intensity
In the ddAC group, the calculated RDIs for doxorubicin and cyclophosphamide were 97.5% and 98.1%, respectively. The corresponding values in the EC group were 96.0% and 97.5%, respectively. The average RDIs of administered ddAC and EC were 97.9% and 96.8%, respectively (P = 0.28; Table 4 ). Of the 41 patients who received ddAC, only one had an RDI <85% (2.4%). None of the 56 patients who received EC had an RDI <85% (Fig. 1) .
Dose delay and dose reduction
Dose delay was observed in 2 of 41 (4.9%) patients in the ddAC group: one patient had an infected surgical wound and the other had an abnormally decreased platelet count. Nine of the 56 (16.1%) patients in the EC group also experienced dose delays (P = 0.11) attributed to neutropenia (n = 7), abnormally elevated hepatic enzymes (n = 1) and infection of the tissue expander (n = 1). Although dose reduction was observed in 4 of 56 patients (7.1%) in the EC group, none in the ddAC group required dose reduction (P = 0.16; Table 3 ).
Incidence of regimen change and hospitalization because of neutropenia
No patient in either group required a regimen change or hospitalization because of neutropenia (Table 3) .
Discussion
To the best of our knowledge, this study, wherein we evaluated the efficacy of a 3.6-mg dose of pegfilgrastim as a prophylaxis against FN, is the first to evaluate the feasibility of this pegfilgrastim dose in breast cancer patients treated using dose-dense chemotherapy. We found that FN occurred in only 2.4% of patients in the ddAC group during any chemotherapy cycle compared with 14.3% in the EC group, which is a significant reduction. In addition, the incidences of dose delay and reduction were lower among patients in the ddAC group, although these differences were not significant. We further observed high average RDI values for both groups. We sought the reasons why RDI was as high as 96.8% in the EC group while it Table 2 . Incidence of most common treatment-related AEs excluding alopecia seems to be more delay and dose reduction are, first, patients who had delay and dose reduction in EC group were small in number, and second, dose reduction was performed only in epirubicin and not in cyclophosphamide. Only one patient in the ddAC group and none in the EC group had an RDI of <85%. Therefore, our results indicate that ddAC plus 3.6 mg of pegfilgrastim yielded lower incidence rates of FN during all cycles of chemotherapy, dose delay and dose reduction as well as an RDI level similar to that of EC. Dose-dense biweekly adjuvant chemotherapy regimens comprising AC followed by paclitaxel are being widely used. The CALGB 9741 trial compared AC followed by paclitaxel administered using a traditional triweekly schedule against a dose-dense schedule with G-CSF support and demonstrated that the dose-dense schedule could improve both OS and DFS relative to the traditional schedule. However, in the CALGB 9741 trial, the use of filgrastim reduced the incidence of FN in the dose-dense treatment arms to a rate of 2-3%. Subsequently, the Dana-Farber Cancer Institute developed a phase II trial of 135 patients to evaluate the use of 6 mg pegfilgrastim in support of this dose-dense regimen, using the same chemotherapy regimen as the CALGB 9741 trial (four cycles of doxorubicin at 60 mg/ m 2 and cyclophosphamide at 600 mg/m 2 every 14 days, followed by paclitaxel 175 mg/m 2 once every 2 weeks); pegfilgrastim was subcutaneously administered in 6-mg doses on day 2 of each treatment cycle. FN developed in only 2 of 135 patients (1.5%) (25) . Our study achieved an FN incidence of 2.4% with a 3.6-mg dose of pegfilgrastim, which was comparable to the results of the CALGB 9741 trial and subsequent phase II trial of 6-mg pegfilgrastim.
A recent randomized phase II study of 56 patients hypothesized that a dose-dense regimen comprising docetaxel at 75 mg/m 2 every 14 days followed by ddAC (doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 ) every 14 days for four cycles with 6 mg pegfilgrastim would yield a higher RDI than the reverse sequence. Accordingly, that study yielded RDI values of 95% and 98% with 6 mg pegfilgrastim, respectively (26) . The present study achieved a comparable average RDI for administered ddAC of 97.9% with 3.6 mg pegfilgrastim. Two clinical trials have evaluated the use of 3.6 mg pegfilgrastim. First, a phase II study (n = 87) was performed to evaluate the recommended dose of pegfilgrastim. Patients with stage II/III invasive breast cancer were administered single 1.8-, 3.6-, or 6.0-mg doses of pegfilgrastim per TAC therapy cycle, and the results indicated a peak of pegfilgrastim efficacy at 3.6 mg. In this phase II study, the overall incidence of FN in all cycles was 3 of 29 (10.3%) patients in the 3.6-mg group (23) . A subsequent phase III trial (n = 357) of the prophylactic use of 3.6 mg pegfilgrastim was conducted in breast cancer patients receiving TC chemotherapy. In that study, the incidence of FN in all cycles was 2 of 173 patients (1.2%) (24) . In comparison with these trials, which were based on triweekly regimens involving 3.6 mg pegfilgrastim, our results obtained using a dose-dense regimen confirmed a similar efficacy level of pegfilgrastim, with an overall incidence of FN of only 1 of 41 patients (2.4%) receiving ddAC with 3.6 mg pegfilgrastim.
One major limitation of this study was the design as a nonrandomized, retrospective chart review; in addition, the study had a small sample size obtained from a single oncology center. Furthermore, different treatment regimens were used for the study groups. The definition of FN is also known to vary between Japan and western countries. Although verification via a larger trial is needed, our preliminary findings indicate that the use of 3.6 mg pegfilgrastim as a primary prophylaxis maintained the RDI of dose-dense chemotherapy and was effective for the primary prevention of FN resulting from dose-dense chemotherapy in Japanese breast cancer patients.
In summary, this is the first study to evaluate the efficacy of 3.6 mg pegfilgrastim in the context of dose-dense chemotherapy. Despite the stated limitations, our results indicate that this dose of pegfilgrastim can effectively prevent FN consequent to ddAC in Japanese breast cancer patients. In comparison with the approved pegfilgrastim dose of 6 mg used in the United States and European countries, our results suggest that a lower pegfilgrastim dose is adequately efficacious in Japanese breast cancer patients receiving dose-dense chemotherapy.
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